HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soumerai, S B Articles by Hawley, S Search for Related Content PubMed PubMed Citation Articles by Soumerai, S B Articles by Hawley, S

Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene.

S B Soumerai, J Avorn, S Gortmaker and S Hawley

Department of Social Medicine and Health Policy, Harvard Medical School, Boston, MA 02115.

We analyzed trends in prescribing and overdose deaths related to propoxyphene (e.g., Darvon) before and after a 1978-80 informational campaign carried out by the US Food and Drug Administration and the drug's manufacturer through mailed warnings, face-to-face education of prescribers, press releases, and labeling changes. The goals included a reduction in propoxyphene use with alcohol or other CNS depressants, reduced prescribing of refills, and cessation of prescribing for patients at risk of abuse and misuse (suicide). We conducted time-series analyses of nationwide propoxyphene use data 1974-83 and analyzed data on drug overdose death rates covering a combined population of about 83 million. Segmented regression methods were used to determine if the informational program was associated with changes in trends of prescribing or overdose deaths. Comparison drug series were analyzed to control for other secular trends in prescribing. Nationwide propoxyphene use during the warnings continued a pre-existing decline of about 8 per cent per year, but this decline halted after the warnings. The no-refill recommendation had no impact on refill rates. The risk of overdose death per propoxyphene prescription filled has remained about constant since 1979. Sharper declines in misuse of such drugs will require stronger, more sustained regulatory or educational measures.

This article has been cited by other articles:

				M. Olfson, S. C. Marcus, and B. G. Druss Effects of Food and Drug Administration Warnings on Antidepressant Use in a National Sample Arch Gen Psychiatry, January 1, 2008; 65(1): 94 - 101. [Abstract] [Full Text] [PDF]

				L. J Paulozzi Overdoses are injuries too Inj. Prev., October 1, 2007; 13(5): 293 - 294. [Full Text] [PDF]

				B. Darpo Detection and reporting of drug-induced proarrhythmias: room for improvement Europace, September 1, 2007; 9(suppl_4): iv23 - iv36. [Abstract] [Full Text] [PDF]

				S. Simkin, K. Hawton, L. Sutton, D. Gunnell, O. Bennewith, and N. Kapur Co-proxamol and suicide: preventing the continuing toll of overdose deaths QJM, March 1, 2005; 98(3): 159 - 170. [Abstract] [Full Text] [PDF]

				E. Oken, K. P. Kleinman, W. E. Berland, S. R. Simon, J. W. Rich-Edwards, and M. W. Gillman Decline in Fish Consumption Among Pregnant Women After a National Mercury Advisory Obstet. Gynecol., August 1, 2003; 102(2): 346 - 351. [Abstract] [Full Text] [PDF]

				J. K. Jones, D. Fife, S. Curkendall, E. Goehring Jr, J. J. Guo, and M. Shannon Coprescribing and Codispensing of Cisapride and Contraindicated Drugs JAMA, October 3, 2001; 286(13): 1607 - 1609. [Abstract] [Full Text] [PDF]

				T. J. Moore, B. M. Psaty, and C. D. Furberg Time to Act on Drug Safety JAMA, May 20, 1998; 279(19): 1571 - 1573. [Full Text] [PDF]

				K. Bloor and N. Freemantle Fortnightly Review: Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors BMJ, June 15, 1996; 312(7045): 1525 - 1527. [Full Text]